227 related articles for article (PubMed ID: 30982223)
1. Organic Anion Transporter Polypeptide 1B1 Polymorphism Modulates the Extent of Drug-Drug Interaction and Associated Biomarker Levels in Healthy Volunteers.
Yee SW; Giacomini MM; Shen H; Humphreys WG; Horng H; Brian W; Lai Y; Kroetz DL; Giacomini KM
Clin Transl Sci; 2019 Jul; 12(4):388-399. PubMed ID: 30982223
[TBL] [Abstract][Full Text] [Related]
2. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1).
Niemi M; Schaeffeler E; Lang T; Fromm MF; Neuvonen M; Kyrklund C; Backman JT; Kerb R; Schwab M; Neuvonen PJ; Eichelbaum M; Kivistö KT
Pharmacogenetics; 2004 Jul; 14(7):429-40. PubMed ID: 15226675
[TBL] [Abstract][Full Text] [Related]
3. Detection of Weak Organic Anion-Transporting Polypeptide 1B Inhibition by Probenecid with Plasma-Based Coproporphyrin in Humans.
Zhang Y; Holenarsipur VK; Kandoussi H; Zeng J; Mariappan TT; Sinz M; Shen H
Drug Metab Dispos; 2020 Oct; 48(10):841-848. PubMed ID: 32723847
[TBL] [Abstract][Full Text] [Related]
4. Comparative Evaluation of Plasma Bile Acids, Dehydroepiandrosterone Sulfate, Hexadecanedioate, and Tetradecanedioate with Coproporphyrins I and III as Markers of OATP Inhibition in Healthy Subjects.
Shen H; Chen W; Drexler DM; Mandlekar S; Holenarsipur VK; Shields EE; Langish R; Sidik K; Gan J; Humphreys WG; Marathe P; Lai Y
Drug Metab Dispos; 2017 Aug; 45(8):908-919. PubMed ID: 28576766
[TBL] [Abstract][Full Text] [Related]
5. Further Studies to Support the Use of Coproporphyrin I and III as Novel Clinical Biomarkers for Evaluating the Potential for Organic Anion Transporting Polypeptide 1B1 and OATP1B3 Inhibition.
Shen H; Christopher L; Lai Y; Gong J; Kandoussi H; Garonzik S; Perera V; Garimella T; Humphreys WG
Drug Metab Dispos; 2018 Aug; 46(8):1075-1082. PubMed ID: 29777022
[TBL] [Abstract][Full Text] [Related]
6. Coproporphyrin I Can Serve as an Endogenous Biomarker for OATP1B1 Inhibition: Assessment Using a Glecaprevir/Pibrentasvir Clinical Study.
Kalluri HV; Kikuchi R; Coppola S; Schmidt J; Mohamed MF; Bow DAJ; Salem AH
Clin Transl Sci; 2021 Jan; 14(1):373-381. PubMed ID: 33048456
[TBL] [Abstract][Full Text] [Related]
7. Effect of OATP1B1/1B3 Inhibitor GDC-0810 on the Pharmacokinetics of Pravastatin and Coproporphyrin I/III in Healthy Female Subjects.
Liu L; Cheeti S; Yoshida K; Choo E; Chen E; Chen B; Gates M; Singel S; Morley R; Ware J; Sahasranaman S
J Clin Pharmacol; 2018 Nov; 58(11):1427-1435. PubMed ID: 29786857
[TBL] [Abstract][Full Text] [Related]
8. Coproporphyrins in Plasma and Urine Can Be Appropriate Clinical Biomarkers to Recapitulate Drug-Drug Interactions Mediated by Organic Anion Transporting Polypeptide Inhibition.
Lai Y; Mandlekar S; Shen H; Holenarsipur VK; Langish R; Rajanna P; Murugesan S; Gaud N; Selvam S; Date O; Cheng Y; Shipkova P; Dai J; Humphreys WG; Marathe P
J Pharmacol Exp Ther; 2016 Sep; 358(3):397-404. PubMed ID: 27317801
[TBL] [Abstract][Full Text] [Related]
9. Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition.
Gu X; Wang L; Gan J; Fancher RM; Tian Y; Hong Y; Lai Y; Sinz M; Shen H
Drug Metab Dispos; 2020 Aug; 48(8):724-734. PubMed ID: 32482623
[TBL] [Abstract][Full Text] [Related]
10. Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril.
Maeda K; Ieiri I; Yasuda K; Fujino A; Fujiwara H; Otsubo K; Hirano M; Watanabe T; Kitamura Y; Kusuhara H; Sugiyama Y
Clin Pharmacol Ther; 2006 May; 79(5):427-39. PubMed ID: 16678545
[TBL] [Abstract][Full Text] [Related]
11. Identification of Glycochenodeoxycholate 3-O-Glucuronide and Glycodeoxycholate 3-O-Glucuronide as Highly Sensitive and Specific OATP1B1 Biomarkers.
Neuvonen M; Hirvensalo P; Tornio A; Rago B; West M; Lazzaro S; Mathialagan S; Varma M; Cerny MA; Costales C; Ramanathan R; Rodrigues AD; Niemi M
Clin Pharmacol Ther; 2021 Mar; 109(3):646-657. PubMed ID: 32961594
[TBL] [Abstract][Full Text] [Related]
12. Repaglinide-irbesartan drug interaction: effects of SLCO1B1 polymorphism on repaglinide pharmacokinetics and pharmacodynamics in Chinese population.
Pei Q; Liu JY; Yin JY; Yang GP; Liu SK; Zheng Y; Xie P; Guo CX; Luo M; Zhou HH; Li X; Liu ZQ
Eur J Clin Pharmacol; 2018 Aug; 74(8):1021-1028. PubMed ID: 29748863
[TBL] [Abstract][Full Text] [Related]
13. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin.
Niemi M; Pasanen MK; Neuvonen PJ
Clin Pharmacol Ther; 2006 Oct; 80(4):356-66. PubMed ID: 17015053
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of the organic anion-transporting polypeptide 1B1 by quercetin: an in vitro and in vivo assessment.
Wu LX; Guo CX; Chen WQ; Yu J; Qu Q; Chen Y; Tan ZR; Wang G; Fan L; Li Q; Zhang W; Zhou HH
Br J Clin Pharmacol; 2012 May; 73(5):750-7. PubMed ID: 22114872
[TBL] [Abstract][Full Text] [Related]
15. Rifampin- and Silymarin-Mediated Pharmacokinetic Interactions of Exogenous and Endogenous Substrates in a Transgenic OATP1B Mouse Model.
Bechtold BJ; Lynch KD; Oyanna VO; Call MR; Graf TN; Oberlies NH; Clarke JD
Mol Pharm; 2024 May; 21(5):2284-2297. PubMed ID: 38529622
[TBL] [Abstract][Full Text] [Related]
16. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics.
Niemi M; Backman JT; Kajosaari LI; Leathart JB; Neuvonen M; Daly AK; Eichelbaum M; Kivistö KT; Neuvonen PJ
Clin Pharmacol Ther; 2005 Jun; 77(6):468-78. PubMed ID: 15961978
[TBL] [Abstract][Full Text] [Related]
17. Effects of single nucleotide polymorphisms and haplotypes of the SLCO1B1 gene on the pharmacokinetic profile of atorvastatin in healthy Macedonian volunteers.
Daka A; Dimovski A; Kapedanovska A; Vavlukis M; Eftimov A; Labachevski N; Jakjovski K; Geshkovska MN; Nebija D; Mladenovska K
Pharmazie; 2015 Jul; 70(7):480-8. PubMed ID: 26373210
[TBL] [Abstract][Full Text] [Related]
18. Development of an LC-MS method to quantify coproporphyrin I and III as endogenous biomarkers for drug transporter-mediated drug-drug interactions.
Njumbe Ediage E; Dillen L; Vroman A; Diels L; Kunze A; Snoeys J; Verhaeghe T
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Jan; 1073():80-89. PubMed ID: 29241088
[TBL] [Abstract][Full Text] [Related]
19. Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants.
Ho RH; Choi L; Lee W; Mayo G; Schwarz UI; Tirona RG; Bailey DG; Stein CM; Kim RB
Pharmacogenet Genomics; 2007 Aug; 17(8):647-56. PubMed ID: 17622941
[TBL] [Abstract][Full Text] [Related]
20. Metabolomic and Genome-wide Association Studies Reveal Potential Endogenous Biomarkers for OATP1B1.
Yee SW; Giacomini MM; Hsueh CH; Weitz D; Liang X; Goswami S; Kinchen JM; Coelho A; Zur AA; Mertsch K; Brian W; Kroetz DL; Giacomini KM
Clin Pharmacol Ther; 2016 Nov; 100(5):524-536. PubMed ID: 27447836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
